Market Overview

UPDATE: Goldman Sachs Raises PT on Stryker Corporation on Completed Acquisition, Updated Model

Share:
Related SYK
Earnings Scheduled For July 27, 2017
FDA's 60-Day Extension For Medical Device Defects Not Likely Obstructive To Public Health

In a report published Monday, Goldman Sachs reiterated its Buy rating on Stryker Corporation (NYSE: SYK), and slightly raised its price target from $71.00 to $72.00.

Goldman Sachs noted, “We update our model for the completed acquisition of Trauson Holdings and the announced $250mn ASR. Trauson is an orthopaedic device manufacturer headquartered in China with a primary focus on trauma and spine (77% of sales combined). 2012 revenue was around $75-80 million, growing at 25-30%. Stryker management indicated the transaction to be neutral to 2013E EPS and accretive thereafter. We believe there could be further upside to estimates should Stryker prove successful at leveraging Trauson's existing channels in China to sell a broader product suite.”

Stryker Corporation closed on Friday at $64.90.

Latest Ratings for SYK

DateFirmActionFromTo
Jun 2017Cantor FitzgeraldInitiates Coverage OnNeutral
May 2017Goldman SachsInitiates Coverage OnNeutral
Dec 2016UBSUpgradesNeutralBuy

View More Analyst Ratings for SYK
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Price Target Analyst Ratings

 

Related Articles (SYK)

View Comments and Join the Discussion!